Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Trade Show, Webcast

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 3:00 p.m. ET.

A live webcast of the presentation will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 18:00
Voxtur Engages ICP Securities Inc. for Automated Market Making Services
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

at 18:00
Portland General Electric declares dividend
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

at 17:52
ADYTON RESOURCES CORPORATION ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT
Adyton Resources Corporation  ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...

at 17:20
NCPDP's National Facilitator Model Pilot Project Enters Second Phase
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
Lion Group Holding Announced Receipt of Nasdaq Listing Delinquency Notice
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...

at 16:30
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
Cosmos Health Inc. ("Cosmos Health" or the "Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor...

More news about Covid-19 virus...


News published on and distributed by: